[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349636-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349636-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","probiotic-carriers-for-tumor-targeted-therapy-applications-and-challenges","Probiotic Carriers for Tumor-Targeted Therapy: Applications and Challenges","","Cancer poses an escalating threat to global public health, with incidence and mortality rising and projected deaths reaching 29.4 million by 2040. Conventional interventions such as surgery, chemotherapy, and radiotherapy are limited by systemic toxic side effects, insufficient targeting precision, and frequent treatment-related sequelae. Nanodrug delivery aims to improve tumor targeting and reduce toxicity, but conventional nanocarriers are rapidly cleared and face impaired penetration due to a heterogeneous tumor microenvironment. Probiotics offer tumor tropism and adaptive, TME-responsive remodeling, with strong synergy across therapeutic regimens, and the review details mechanisms, engineering strategies, hybrid systems, and key bottlenecks for clinical translation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/probiotic-carriers-for-tumor-targeted-therapy-applications-and-challenges/349636/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/probiotic-carriers-for-tumor-targeted-therapy-applications-and-challenges/349636.png","ImageObject",300,407,{"name":42,"@type":43},"acoobca","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are conventional cancer treatments limited in effectiveness and safety?","Question",{"text":63,"@type":64},"Surgery, chemotherapy, and radiotherapy can be constrained by systemic toxic side effects, inadequate targeting precision, and frequent severe postoperative or treatment-related sequelae, leading to limited overall clinical efficacy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What main obstacles reduce nanodrug delivery to solid tumors?",{"text":68,"@type":64},"Conventional carriers are rapidly cleared by the mononuclear phagocyte system, and the heterogeneous tumor microenvironment (TME) blocks effective intratumoral penetration and uniform drug distribution.",{"name":70,"@type":61,"acceptedAnswer":71},"What advantages do probiotics provide for tumor-targeted therapy?",{"text":72,"@type":64},"Probiotics can home to tumors, adapt to and remodel the TME, and show excellent compatibility and synergy with multiple therapeutic regimens, supporting more effective and targeted delivery.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349636,1790626724,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","International Journal of Nanomedicine  \n Open Access Full Text Article  \nREVIEW  \nProbiotic Carriers for Tumor-Targeted Therapy: Applications and Challenges  \nJingyi Hao 1 , *, Jialin Li2 , *, Hang Zhu 1 , Ziyi Wang 1 , Wenhe Zhu 3 , Hao Wu 1 , Yawei Li 1  \n1Department of Pharmacy, Jilin Medical University, Jilin, Jilin Province, People’s Republic of China; 2Drug Clinical Trial Center, Siping Central People’s Hospital, Siping, Jilin Province, People’s Republic of China; 3Research and Experimental Center, Jilin Medical University, Jilin, Jilin Province, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Hao Wu; Yawei Li, Email [jlmuhaowu@163.com](jlmuhaowu@163.com); [lyw135@163.com](lyw135@163.com)  \n\n| Abstract: Cancer poses an escalating threat to global public health, characterized by continuous rises in both incidence and mortality. While conventional tumor interventions including surgery, chemotherapy and radiotherapy have made considerable progress, their clinical efficacy is severely constrained by systemic toxic side effects, inadequate targeting precision and frequent severe postoperative and treatment-related sequelae. Nanodrug delivery systems have evolved as a viable therapeutic alternative to optimize tumor targeting and minimize systemic toxicity. However, conventional nanocarriers suffer from rapid clearance by the mononuclear phagocyte system, and the intricate, heterogeneous tumor microenvironment (TME) further impairs effective intratumoral drug penetration and uniform distribution. As an emerging class of living delivery vectors, probiotics have recently gained extensive research attention by virtue of their intrinsic tumor tropism, unique capacity to adapt to and remodel the TME, and excellent synergistic compatibility with multiple therapeutic regimens. This review systematically elaborates the biological mechanisms governing the tumor-targeted accumulation and TME-responsive properties of probiotics, summarizes core strategies for probiotic genetic modification and hybrid system construction, and compares the strengths and applicable scenarios of diverse probiotic chassis strains. We further discuss the synergistic potential of probiotic-based platforms combined with immunotherapy, chemotherapy, radiotherapy and physical therapy. Finally, this article underscores the key bottlenecks and future research directions for the clinical translation of probiotic-based antitumor therapeutics, aiming to provide rigorous theoretical support for their broader clinical application in cancer treatment. Keywords: probiotics, engineering strategies, combination therapy |\n| --- |\n| Introduction\u003Cbr>Cancer, which is one of the most important challenges in global public health. Its incidence and mortality continue to increase, and the number of deaths is projected to reach 29.4 million by 2040.1 The prevention and treatment of highincidence malignancies such as colorectal cancer, gastric cancer, and breast cancer remain especially daunting.2 Current clinical treatments mainly include surgery, radiotherapy, and chemotherapy, yet all have significant limitations.3–5 Although surgery can be curative at an early stage, more than 70% of patients are diagnosed at middle or late stages, thereby missing the optimal window for surgical intervention.6 Accordingly, there is an urgent need to develop novel anti-tumor strategies that are more effective and less toxic.\u003Cbr>Nanodrug delivery systems, as an important area of tumor therapy research, can achieve tumor targeting to a certain extent while reducing systemic adverse effects. Based on the enhanced permeability and retention (EPR) effect, nanomedicines can selectively accumulate at tumor sites. Carriers such as poly (lactic-co-glycolic acid) nanoparticles, liposomes, and iron nanoparticles have been widely used in cancer therapy.7,8 However, because drug carriers are rapidly cleared by the mononuclear phagocyte system in the liver and splee","cbCailpKmf62Fev7","https://ap.wps.com/l/cbCailpKmf62Fev7","pdf",15415830,29,"English","# Introduction\n## Limitations of current cancer treatments\n## Nanodrug delivery systems and challenges\n## Promise of probiotic delivery carriers","[{\"question\":\"Why are conventional cancer treatments limited in effectiveness and safety?\",\"answer\":\"Surgery, chemotherapy, and radiotherapy can be constrained by systemic toxic side effects, inadequate targeting precision, and frequent severe postoperative or treatment-related sequelae, leading to limited overall clinical efficacy.\"},{\"question\":\"What main obstacles reduce nanodrug delivery to solid tumors?\",\"answer\":\"Conventional carriers are rapidly cleared by the mononuclear phagocyte system, and the heterogeneous tumor microenvironment (TME) blocks effective intratumoral penetration and uniform drug distribution.\"},{\"question\":\"What advantages do probiotics provide for tumor-targeted therapy?\",\"answer\":\"Probiotics can home to tumors, adapt to and remodel the TME, and show excellent compatibility and synergy with multiple therapeutic regimens, supporting more effective and targeted delivery.\"}]","Probiotic Carriers for Tumor-Targeted Therapy: Applications and Challenges | PDF",1790084618,73,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1194d397809ffdd38c84e840cae49ddd.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76f2f1cd7dd4f944cc2c1b7a4a6b0afe.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/874b62e58494906aecb20053f1a0a51d.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8fadc6b5006cebfb7d18a9b5df310078.webp",980,1268]